SCHOTT to Invest in its Pharmaceutical Tubing Business in South America
The investment covers the latest update of the company’s perfeXion® process, an on-line inspection system that examines every tube, as well as implementing state-of-the-art production technology in glass-melting furnaces.
SCHOTT recently announced that it is investing BRL 50 million (approximately $12.9 million) in its pharmaceutical tubing production in Rio de Janeiro over the next two years. The investment covers the latest update of the company’s perfeXion® process, an on-line inspection system that examines every tube, as well as implementing state-of-the-art production technology in glass-melting furnaces.
Quality control is a key aspect in the pharmaceutical industry, with regulatory agencies and pharmaceutical groups increasingly reinforcing the need for a 100% inspection of glass tubing to detect possible defects. Therefore, SCHOTT is enhancing its existing perfeXion quality approach in its plant in Rio, which replaces statistical sample-based quality assurance with 100% on-line measurement of each individual FIOLAX tube. Several inspection and interaction devices, in combination with integrated data collection and analysis, enable parameters to be adapted to the packaging type format and customer-required specifications.
“In line with our zero defect approach, we already established a new era in quality processing for pharmaceutical tubing with perfeXion,” said Joerg Wagner, technical director of SCHOTT Brazil Division Vitrofarma. “Now, the investment allows us to further optimize the machinery to continue setting new standards in the pharma glass industry.
The investment also features the implementation of a highly advanced production technology in all glass-melting furnaces. This enables the company to manufacture a product of even higher quality and contribute to the environment by reducing fossil fuel consumption and emission of greenhouse gases.
To discuss the importance of high-quality pharmaceutical tubing and packaging, SCHOTT recently a technical symposium in Rio de Janeiro. The event reportedly covered information related to the differences between type I glasses, dimensional accuracy and cosmetic quality, the future of the injectable drug manufacturing, and drug delivery systems. Attendees also had the chance to visit the tubing production plant and witness the manufacturing process firsthand.
“We are extremely proud to bring this discussion to the Latin American market and highlight the importance of the region for SCHOTT,” said Peter Scherer, vice president of Marketing and Sales at SCHOTT Tubing. “We believe that technological innovation and the elimination of patient risks are two basic premises that must constantly be present in the policy of companies operating in the pharmaceutical sector.”
For more information, visit www.schott.com.